<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preoperative therapy in patients prospectively declared to require an APR</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preoperative therapy in patients prospectively declared to require an APR</h1>
<div class="graphic"><div class="figure"><div class="ttl">Preoperative therapy in patients prospectively declared to require an APR</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="10" width="9%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Wagman R<sup>1</sup></td> <td class="subtitle1">Rouanet P<sup>2</sup></td> <td class="subtitle1">Hyams DM<sup>3</sup></td> <td class="subtitle1">Kuvshinoff B<sup>4</sup></td> <td class="subtitle1">Valentini V<sup>5</sup></td> <td class="subtitle1">Francois Y<sup>6</sup></td> <td class="subtitle1">Grann A<sup>7</sup></td> <td class="subtitle1">Sauer R<sup>8</sup></td> <td class="subtitle1">Gambacorta M<sup>9</sup></td> <td class="subtitle1">Rengan R<sup>10</sup></td> </tr> <tr> <td>Treatment</td> <td>RT</td> <td>RT</td> <td>CMT</td> <td>CMT</td> <td>CMT</td> <td>RT</td> <td>CMT</td> <td>CMT</td> <td>CMT</td> <td>RT</td> </tr> <tr> <td>Total number enrolled</td> <td>36</td> <td>37</td> <td>59*</td> <td>37</td> <td>83</td> <td>201</td> <td>72</td> <td>392<sup>¶</sup></td> <td>54</td> <td>27</td> </tr> <tr> <td>Number who underwent surgery</td> <td>35</td> <td>27</td> <td>59</td> <td>36</td> <td>81</td> <td>34</td> <td>72</td> <td>NR</td> <td>54</td> <td>27</td> </tr> <tr> <td>Number judged to need an APR</td> <td>36</td> <td>37</td> <td>40</td> <td>37</td> <td>47</td> <td>34*</td> <td>35</td> <td>105</td> <td>20</td> <td>27</td> </tr> <tr> <td>Number with T3 disease</td> <td>31 (86%)</td> <td>12 (32%)</td> <td>NR (100%)</td> <td>NR</td> <td>83 (66%) </td> <td>62 (44%)</td> <td>72 (100%)</td> <td>NR</td> <td>52 (96%)</td> <td>0 (all cT2)</td> </tr> <tr> <td>Number who underwent LAR and/or coloanal anastomosis</td> <td>27 (77%)</td> <td>17 (63%)</td> <td>30 (75%)</td> <td>28 (78%)</td> <td>31 (66%)</td> <td>15 (44%)</td> <td>68 (94%)</td> <td>41 (39%)</td> <td>13 (65%)</td> <td>21 (78%)</td> </tr> <tr> <td>Percent local failure</td> <td>17</td> <td>8</td> <td>NR</td> <td>11</td> <td>10</td> <td>12</td> <td>2</td> <td>7</td> <td>4</td> <td>10</td> </tr> <tr> <td>Percent survival</td> <td>64% 5-year</td> <td>83% 2-year</td> <td>NR</td> <td>87%<sup>Δ</sup></td> <td>72% 5-year</td> <td>75% 3-year</td> <td>95% 3-year </td> <td>78% 5-year</td> <td>92% 2-year</td> <td>86% 5-year</td> </tr> <tr> <td>Number evaluable for sphincter function analysis</td> <td>27 (77%)</td> <td>14 (52%)</td> <td>NR</td> <td>NR</td> <td>63</td> <td>82§</td> <td>21</td> <td>NR</td> <td>NR</td> <td>21</td> </tr> <tr> <td>Sphincter function</td> <td>85% good to excellent</td> <td>75% perfect</td> <td>NR</td> <td>NR</td> <td>6% moderate soilage</td> <td>78% normal</td> <td>81% good to excellent</td> <td>NR</td> <td>NR</td> <td>77% good to excellent at 2 to 3 years</td> </tr> </tbody></table></div><div class="graphic_footnotes">APR: abdominoperineal resection; RT: radiation therapy; CMT: combined modality therapy; NR: data not reported; cT2: clinical (and endoscopy) stage T2.<br/>* These data are from an early report of National Surgical Adjuvant Breast and Bowel Project (NSABP) R-03 that included 59 patients randomized to the preoperative arm, 40 of whom were judged to require APR. Data on patients in the postoperative arm are not included.<br/>¶ Data from a preliminary report of the preoperative therapy arm of a randomized German study comparing preoperative and postoperative chemoradiotherapy.<br/>Δ Disease-free survival with a median follow-up of 12 months.</div><div class="graphic_reference">References:<br/><ol>
<li>Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998; 42:51.</li>
<li>Rouanet P, Saint-Aubert B, Lemanski C, et al. Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results. Dis Colon Rectum 2002; 45:305.</li>
<li>Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997; 40:131.</li>
<li>Kuvshinoff B, Maghfoor I, Miedema B, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are &lt; or = 1 cm distal margins sufficient? Ann Surg Oncol 2001; 8:163.</li>
<li>Valentini V, Coco C, Picciocchi A, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998; 40:1067.</li>
<li>Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17:2396.</li>
<li>Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 49:987.</li>
<li>Sauer R. Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer: first results of the German rectal cancer study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 2003; 57(2 suppl): S124.</li>
<li>Gambacorta M, Valentini V, Morganti AG, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys 2004; 60:130.</li>
<li>Rengan R, Paty P, Wong WD, et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? J Clin Oncol 2005; 23:4905.</li></ol></div><div id="graphicVersion">Graphic 63971 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
